Login / Signup

Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors.

Yan LiPu KuangHuanling ZhuLing PanTian DongTing LinYu ChenYunfan Yang
Published in: Therapeutic advances in hematology (2024)
Lowering the TKI dose can effectively preserve a deep molecular response over time while relieving adverse events caused by TKIs.
Keyphrases
  • low dose
  • chronic myeloid leukemia
  • high dose
  • tyrosine kinase
  • single molecule